Anti‐inflammatory effects of α7‐nicotinic ACh receptors are exerted through interactions with adenylyl cyclase‐6

Simeng Zhu,Shiqian Huang,Guofang Xia,Jin Wu,Yan Shen,Ying Wang,Rennolds S. Ostrom,Ailian Du,Chengxing Shen,Congfeng Xu
DOI: https://doi.org/10.1111/bph.15412
IF: 7.3
2021-04-04
British Journal of Pharmacology
Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background and purpose</h3><p>Alpha 7 nicotinic acetylcholine receptors (CHRNA7) suppress inflammation through diverse pathways in immune cells, so is potentially involved in a number of inflammatory diseases. However, the detailed mechanisms underlying CHRNA7's anti‐inflammatory effects remain elusive.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Experimental approach</h3><p>The anti‐inflammatory effects of CHRNA7 agonists in both murine macrophages (RAW 264.7) and bone marrow‐derived macrophages (BMDM) stimulated with LPS were examined. The role of adenylyl cyclase 6 (AC6) in Toll‐like Receptor 4 (TLR4) degradation was explored via overexpression and knockdown. A mouse model of chronic obstructive pulmonary disease was used to confirm key findings.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Anti‐inflammatory effects of CHRNA7 were largely dependent on AC6 activation, as knockdown of AC6 considerably abnegated the effects of CHRNA7 agonists while AC6 overexpression promoted them. We found that CHRNA7 and AC6 are co‐localized in lipid rafts of macrophages and directly interact. Activation of AC6 led to the promotion of TLR4 degradation. Administration of CHRNA7 agonist PNU‐282987 attenuated pathological and inflammatory end points in a mouse model of chronic obstructive pulmonary disease (COPD).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion and implications</h3><p>CHRNA7 inhibits inflammation through activating AC6 and promoting degradation of TLR4. The use of CHRNA7 agonists may represent a novel therapeutic approach for treating COPD and likely other inflammatory diseases.</p></section>
pharmacology & pharmacy
What problem does this paper attempt to address?
The paper attempts to address the issue of how α7-nicotinic acetylcholine receptors (α7-nAChRs) exert anti-inflammatory effects through their interaction with adenylyl cyclase-6 (AC6). Specifically, the study aims to elucidate how α7-nAChRs activation inhibits inflammatory responses via AC6-mediated cAMP production and Toll-like receptor 4 (TLR4) degradation. ### Background and Objectives - **Background**: α7-nicotinic acetylcholine receptors (α7-nAChRs) inhibit inflammation in immune cells through various pathways, potentially playing a role in multiple inflammatory diseases. However, the specific mechanisms of α7-nAChRs' anti-inflammatory effects remain unclear. - **Objectives**: To investigate how α7-nAChRs exert anti-inflammatory effects through their interaction with adenylyl cyclase-6 (AC6). ### Experimental Methods - **Cell Experiments**: Evaluate the anti-inflammatory effects of α7-nAChR agonists in LPS-stimulated mouse macrophages (RAW 264.7) and bone marrow-derived macrophages (BMDM) using immunoblotting, RT-PCR, and luciferase reporter assays. - **Molecular Mechanism Study**: Explore the role of AC6 in TLR4 degradation following endocytosis by overexpressing and knocking down AC6. - **Animal Model**: Validate key findings using a mouse model of chronic obstructive pulmonary disease (COPD) induced by porcine pancreatic elastase. ### Results - **The anti-inflammatory effect of α7-nAChRs depends on AC6 activation**: Knockdown of AC6 significantly reduced the effects of α7-nAChR agonists, while overexpression of AC6 enhanced these effects. - **α7-nAChRs and AC6 co-localize in lipid rafts and directly interact**: Activation of AC6 increased TLR4 degradation. - **The α7-nAChR agonist PNU-282987 alleviated pathological and inflammatory endpoints in the COPD mouse model**. ### Conclusion and Significance - **Conclusion**: α7-nAChRs inhibit inflammation by activating AC6 and promoting TLR4 degradation. - **Significance**: Using α7-nAChR agonists may become a new therapy for treating COPD and other inflammatory diseases. ### Keywords - AC6, α7-nAChR, COPD, inflammation, macrophages ### Innovations of the Study - **Increased interaction between α7-nAChRs and AC6**: α7-nAChR agonists can enhance this interaction. - **α7-nAChRs activation promotes TLR4 degradation**: This process is mediated by AC6. ### Clinical Significance - **AC6 is a new target in the anti-inflammatory pathway initiated by α7-nAChRs**.